These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 18412255)

  • 1. The incidence of clinically significant contrast-induced nephropathy following non-emergent coronary angiography.
    Weisbord SD; Hartwig KC; Sonel AF; Fine MJ; Palevsky P
    Catheter Cardiovasc Interv; 2008 Jun; 71(7):879-85. PubMed ID: 18412255
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Implications of Contrast-Induced Nephropathy in Patients Without Baseline Renal Dysfunction Undergoing Coronary Angiography.
    Chen SQ; Liu Y; Smyth B; Li HL; Sun GL; Chen ZJ; Zhou YL
    Heart Lung Circ; 2019 Jun; 28(6):866-873. PubMed ID: 29960836
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of the definition utilized on the rate of contrast-induced nephropathy in percutaneous coronary intervention.
    Jabara R; Gadesam RR; Pendyala LK; Knopf WD; Chronos N; Chen JP; Viel K; King SB; Manoukian SV
    Am J Cardiol; 2009 Jun; 103(12):1657-62. PubMed ID: 19539072
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Clinical impact of nephropathy induced by contrast medium in patients with acute myocardial infarction undergoing emergent coronary angiography].
    Jujo K; Yamaguchi J; Obayashi K; Suzuki K; Sekiguchi H; Nagashima M; Tsurumi Y; Kasanuki H
    J Cardiol; 2006 Jul; 48(1):9-16. PubMed ID: 16886495
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CHA2DS2-VASC score as a preprocedural predictor of contrast-induced nephropathy among patients with chronic total occlusion undergoing percutaneous coronary intervention: a single-center experience.
    Wang Y; Zhao HW; Zhang XJ; Chen BJ; Yu GN; Hou AJ; Luan B
    BMC Cardiovasc Disord; 2019 Mar; 19(1):74. PubMed ID: 30922230
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A prospective, double-blind, randomized, controlled trial on the efficacy and cardiorenal safety of iodixanol vs. iopromide in patients with chronic kidney disease undergoing coronary angiography with or without percutaneous coronary intervention.
    Nie B; Cheng WJ; Li YF; Cao Z; Yang Q; Zhao YX; Guo YH; Zhou YJ
    Catheter Cardiovasc Interv; 2008 Dec; 72(7):958-65. PubMed ID: 19021282
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is treatment with N-acetylcysteine to prevent contrast-induced nephropathy when using bicarbonate hydration out of date?
    Heng AE; Cellarier E; Aublet-Cuvelier B; Decalf V; Motreff P; Marcaggi X; Deteix P; Souweine B
    Clin Nephrol; 2008 Dec; 70(6):475-84. PubMed ID: 19049703
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of contrast-induced nephrotoxicity of iodixanol and iopromide in patients with renal insufficiency undergoing coronary angiography.
    Shin DH; Choi DJ; Youn TJ; Yoon CH; Suh JW; Kim KI; Cho YS; Cho GY; Chae IH; Kim CH
    Am J Cardiol; 2011 Jul; 108(2):189-94. PubMed ID: 21545991
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prediction of contrast-induced nephropathy by the serum creatinine level on the day following cardiac catheterization.
    Watanabe M; Saito Y; Aonuma K; Hirayama A; Tamaki N; Tsutsui H; Murohara T; Ogawa H; Akasaka T; Yoshimura M; Sato A; Takayama T; Sakakibara M; Suzuki S; Ishigami K; Onoue K;
    J Cardiol; 2016 Nov; 68(5):412-418. PubMed ID: 26708123
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictive factors of contrast-induced nephropathy in patients undergoing primary coronary angioplasty.
    Ivanes F; Isorni MA; Halimi JM; Fauchier L; Saint Etienne C; Babuty D; Angoulvant D; Brunet-Bernard A
    Arch Cardiovasc Dis; 2014; 107(8-9):424-32. PubMed ID: 25082735
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preventive effect of pretreatment with intravenous nicorandil on contrast-induced nephropathy in patients with renal dysfunction undergoing coronary angiography (PRINCIPLE Study).
    Ko YG; Lee BK; Kang WC; Moon JY; Cho YH; Choi SH; Hong MK; Jang Y; Kim JY; Min PK; Kwon HM;
    Yonsei Med J; 2013 Jul; 54(4):957-64. PubMed ID: 23709432
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Age, glomerular filtration rate, ejection fraction, and the AGEF score predict contrast-induced nephropathy in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention.
    Andò G; Morabito G; de Gregorio C; Trio O; Saporito F; Oreto G
    Catheter Cardiovasc Interv; 2013 Nov; 82(6):878-85. PubMed ID: 23703775
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of Different Risk Scores for Predicting Contrast Induced Nephropathy and Outcomes After Primary Percutaneous Coronary Intervention in Patients With ST Elevation Myocardial Infarction.
    Liu YH; Liu Y; Zhou YL; He PC; Yu DQ; Li LW; Xie NJ; Guo W; Tan N; Chen JY
    Am J Cardiol; 2016 Jun; 117(12):1896-903. PubMed ID: 27161818
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The ratio of contrast volume to glomerular filtration rate predicts outcomes after percutaneous coronary intervention for ST-segment elevation acute myocardial infarction.
    Mager A; Vaknin Assa H; Lev EI; Bental T; Assali A; Kornowski R
    Catheter Cardiovasc Interv; 2011 Aug; 78(2):198-201. PubMed ID: 20949583
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relation of homocysteinemia to contrast-induced nephropathy in patients undergoing percutaneous coronary intervention.
    Kim SJ; Choi D; Ko YG; Kim JS; Han SH; Kim BK; Kang SW; Hong MK; Jang Y; Choi KH; Yoo TH
    Am J Cardiol; 2011 Oct; 108(8):1086-91. PubMed ID: 21791335
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incidence of Contrast-Induced Nephropathy After Renal Graft Catheter Arteriography Using Iodine-Based Contrast Medium.
    Fananapazir G; Troppmann C; Corwin MT; Bent CK; Vu CT; Lamba R
    AJR Am J Roentgenol; 2016 Apr; 206(4):783-6. PubMed ID: 26866337
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A simple risk score model for predicting contrast-induced nephropathy after coronary angiography in patients with diabetes.
    Zeng JF; Chen SQ; Ye JF; Chen Y; Lei L; Liu XQ; Liu Y; Wang Y; Lin JJ; Chen JY
    Clin Exp Nephrol; 2019 Jul; 23(7):969-981. PubMed ID: 31049747
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Brain natriuretic peptide for prevention of contrast-induced nephropathy after percutaneous coronary intervention or coronary angiography.
    Liu JM; Xie YN; Gao ZH; Zu XG; Li YJ; Hao YM; Chang L
    Can J Cardiol; 2014 Dec; 30(12):1607-12. PubMed ID: 25418218
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of iodixanol and ioversol for the prevention of contrast-induced nephropathy in diabetic patients after coronary angiography or angioplasty.
    Hernández F; Mora L; García-Tejada J; Velázquez M; Gómez-Blázquez I; Bastante T; Albarrán A; Andreu J; Tascón J
    Rev Esp Cardiol; 2009 Dec; 62(12):1373-80. PubMed ID: 20038403
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preventive effect of oral nicorandil on contrast-induced nephropathy in patients with renal insufficiency undergoing elective cardiac catheterization.
    Fan Y; Wei Q; Cai J; Shi Y; Zhang Y; Yao L; Wang X; Lin S; Li Y; Lv J; Zhou B; Du R
    Heart Vessels; 2016 Nov; 31(11):1776-1782. PubMed ID: 26874946
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.